TEVA is trading 4.1% down at $33.24 today, as broader macro-driven weakness in the pharmaceutical sector weighs on investor sentiment, despite positive news regarding its vitiligo program.
- Teva announced plans on July 7, 2026, to advance its investigational anti-interleukin-15 monoclonal antibody (TEV-408) into a Phase 2b study for vitiligo in Q4 2026, following encouraging Phase 1b results.
- The company reported that TEV-408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed.
- The decline in Teva's shares appears tied to broader weakness among large-cap pharmaceutical peers, with sector-wide pressure outweighing the company-specific positive pipeline news.